Plant Name: Callicarpa pilosissima
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.945E-14 | 5.041E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.372E-12 | 7.469E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.576E-12 | 2.232E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.150E-12 | 2.232E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.023E-10 | 4.405E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.772E-10 | 1.469E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.264E-09 | 2.738E-06 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.374E-09 | 3.499E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.597E-09 | 3.561E-06 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.240E-07 | 7.498E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.919E-07 | 5.070E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0001523; retinoid metabolic process | 1.001E-06 | 5.070E-04 | ALDH1A1, CYP1A1, CYP1B1, PPARD |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 2.080E-06 | 9.242E-04 | ALDH1A1, CYP1A1, CYP1B1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.186E-06 | 9.520E-04 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.370E-06 | 1.669E-03 | CYP1A1, CYP1A2 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 6.993E-06 | 2.625E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, RAB9A |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 7.279E-06 | 2.687E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 9.921E-06 | 3.562E-03 | CDK8, CDK9, PPARA, PPARD |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.091E-05 | 3.833E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.527E-05 | 5.038E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.035E-05 | 6.422E-03 | CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.707E-11 | 2.024E-09 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.861E-09 | 4.001E-08 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.370E-09 | 4.831E-08 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 8.372E-09 | 9.000E-08 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.984E-07 | 2.139E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.473E-07 | 1.267E-06 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.943E-06 | 3.036E-05 | CYP1A2; CYP1A1; CYP1B1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.819E-04 | 2.053E-03 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP2C19; CYP3A4 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.133E-04 | 3.886E-03 | CYP1A1; CYP1B1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.248E-03 | 5.366E-03 | CYP2C9; CYP2C19 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.543E-03 | 5.850E-03 | PPARA; PPARD |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.633E-03 | 5.850E-03 | CYP3A4; ABCG2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.001E-03 | 1.303E-02 | CYP2C9; CYP2C19 |
| hsa04142 | Lysosome_Homo sapiens_hsa04142 | 4.803E-03 | 1.377E-02 | NPC1; CTSD |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.214E-02 | 3.263E-02 | PPARA; TSHR |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.243E-03 | 1.303E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PPARD |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | CTSD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CTSD |